Pygeum: Human Evidence, Extracts, and Label Guide

Prunus africana is the accepted botanical name for an African montane tree in the rose family. Pygeum africanum is an older botanical synonym that remains common on supplement labels. Products marketed as Pygeum are usually made from bark, not from the fruit. ¹

Brands mainly market Pygeum for prostate or male urinary support. The name alone does not identify whether a product contains raw bark powder, a concentrated bark extract, a specific lipophilic extract, or a small amount inside a multi-ingredient blend.

An older Cochrane review included 18 randomized trials with 1,562 men who had lower urinary tract symptoms attributed to benign prostatic hyperplasia. Some pooled outcomes favored Pygeum for overall symptoms, urinary flow, residual urine, or nocturia. However, the trials were small, lasted only 30 to 122 days, used different doses and preparations, and often did not use a validated modern symptom score. ²

Cochrane now labels its public summary of this review as historical and outdated. The National Center for Complementary and Integrative Health describes the evidence as limited because studies were short, small, and inconsistent in their methods and formulations. ^{3 4}

A later randomized study compared 50 mg twice daily with 100 mg once daily for two months, followed by an open-label extension. It found similar results between the two schedules, but it did not include a placebo group in the randomized comparison. It cannot establish how much benefit came from the extract itself. ⁵

Clinical guidance is more conservative than supplement marketing. NICE advises against offering phytotherapy for male lower urinary tract symptoms because reliable evidence about effectiveness and safety is insufficient. ⁶

Urinary frequency, weak flow, nocturia, incomplete emptying, and urgency have multiple possible causes. A supplement claim cannot diagnose benign prostatic hyperplasia or rule out infection, obstruction, medicine effects, or another condition.

Some regulatory product contexts use standardized extracts in a 12 to 14 percent phytosterol range, but this does not make one percentage a universal requirement for every product worldwide. A missing 13 percent claim does not prove that a product is fake, and a printed 13 percent claim does not verify identity or laboratory content. ⁸

If a label only shows a raw-herb equivalent, keep both the actual extract mass and the claimed equivalent. They answer different questions. For more context, see the guide to extracts and powders.

These fictional examples show how disclosure changes the interpretation. They are not product recommendations and do not predict a health result.

Takeaway: The largest number is not automatically the most study-relevant disclosure. Compare the material, actual extract amount, marker, full serving, and blend transparency.

The older trials in the Cochrane review used 75 to 200 mg per day of Pygeum extracts, with 100 mg per day used most often. These figures describe specific research preparations and populations, not a general dose for every bark powder, extract, blend, or person. ²

The EMA monograph describes 50 mg twice daily for one specific soft bark extract in a traditional-use context. That preparation is not interchangeable with an unspecified supplement or raw bark powder. ⁹

Kew reports Prunus africana as Vulnerable under the IUCN category data it displays. The species is also listed in CITES Appendix II, which regulates international trade so that trade does not threaten the species’ survival. ^{1 10}

Appendix II is not a declaration that every product is illegally harvested, and Vulnerable is not the same category as Endangered. Responsible sourcing matters, but a consumer label cannot by itself authenticate origin, permits, quotas, plantation status, or harvest practices.

Pygeum extracts were generally reported as well tolerated in the older short-term trials. Digestive effects such as nausea, constipation, or diarrhea were the most consistently reported; headache has also been described. This does not rule out rare effects or establish safety across all extracts, doses, and users. ^{4 9}

New or worsening urinary symptoms should be evaluated rather than self-diagnosed as BPH from age, marketing copy, or a supplement label.